Equity Brief · Healthcare2026-05-20
AMGN·Healthcare

Amgen Inc

I · KI-Analyse

Kurzfassung

Amgen discovers, develops, manufactures, and delivers prescription medicines for serious illnesses including rheumatoid arthritis (Enbrel), high cholesterol (Repatha), osteoporosis (Prolia, Evenity), cancer (Blincyto, Kyprolis, Vectibix), and rare diseases like thyroid eye disease (Tepezza) [Yahoo Finance]. The company sells through doctors' offices, hospitals, dialysis centers, and pharmacies, primarily via pharmaceutical wholesalers [Yahoo Finance].

Amgen is the world's largest independent biotech company, developing and selling medicines for cancer, autoimmune diseases, osteoporosis, and rare conditions [Yahoo Finance]. The company generates $36.7B in annual revenue with strong margins, but faces serious safety concerns around its drug Tavneos, which has been linked to 20 deaths and 22 liver injuries in Japan [Seeking Alpha]. Recent leadership changes include the retirement of CFO Peter Griffith, who will be replaced by returning veteran Thomas Dittrich [Yahoo Finance].

Amgen is financially healthy with strong cash generation and reasonable leverage, earning a 7.4/10 health score [Yahoo Finance].

Kurzfassung AI analysisKonfidenz 8/10

Sentinellis-Score

7.4/10

Financially healthy

Marktkapitalisierung

$178.6B

Umsatz (12 Monate)

$36.7B

II · Aktuelle Nachrichten

Was den Kurs bewegt hat

6 stories · ranked by relevance

  • macro2026-05-19

    AMGEN ANNOUNCES RETIREMENT OF CHIEF FINANCIAL OFFICER PETER GRIFFITH

    Yahoo Finance

  • macro2026-05-18

    Amgen (AMGN) Gets Price Target Cut at Piper Sandler Despite Long-Term Growth Optimism

    Yahoo Finance

  • macro2026-05-18

    Middle East and Africa Wearable Injectors Market Trends and Forecast Report 2026-2035 Featuring Amgen, BD, Biocon, Gerresheimer, Insulet, J&J, Medtronic, Roche, West Pharmaceutical, Ypsomed

    Yahoo Finance

  • macro2026-05-18

    Amgen Japanese Partner Urges Caution On Tavneos Use

    Yahoo Finance

  • macro2026-05-15

    Is It Time To Reassess Amgen (AMGN) After Strong Multi Year Share Price Gains

    Simply Wall St

  • macro2026-05-15

    Amgen Inc. (AMGN) Is a Trending Stock: Facts to Know Before Betting on It

    Zacks

Premium · kostenlos mit jedem Konto

Tavneos faces serious safety scrutiny in Japan after being linked to 20 deaths and 22 liver injuries, which could lead to restricted use, regulatory action, or lawsuits in other markets where Amgen sells the drug [Seeking Alpha]

1 von 4 Risiken in diesem Bericht

Risiken

4

Chancen

5

Warnsignale

3

Führung

10

21 weitere Erkenntnisse im vollständigen Bericht — kostenlos mit jedem Konto.

Vollständige Amgen Inc-Analyse freischalten

Erstellen Sie ein kostenloses Konto für den vollständigen KI-Bericht mit Quellenangaben im Text.

  • 4 Risiken, 5 Chancen und 3 Warnsignale — jeweils mit Quelle
  • Über 100 Finanzkennzahlen mit Charts und Vergleichen
  • Vollständige Nachrichten-Zusammenfassungen mit Quellenlinks
  • Führungsteam und Vergütung
  • PDF-Export für offline
Alle 12 Erkenntnisse freischalten3 kostenlose Berichte · keine Karte

III · Ähnliche Unternehmen

Das könnte Sie auch interessieren

Same sector · Healthcare or comparable health

Auf Ihre Watchlist setzen?

Read three companies free. Keine Karte.

3 kostenlose Berichte sichern